3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
49
Phase NA
27
Phase 1
16
Phase 3
15
Phase 1/2
14
Phase EARLY_PHASE1
6
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
3
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Stomach Neoplasms
1
Pancreatic Adenocarcinoma
1
Pain
1
Neoplasm Metastasis
1
NSCLC
1
Lymphatic Metastasis
1
Colorectal Neoplasms
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Pemetrexed
13
Carboplatin
13
Docetaxel
11
Cisplatin
11
pembrolizumab
9
Paclitaxel
8
Gemcitabine
7
Erlotinib Hydrochloride
4
Bevacizumab
4
anlotinib
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Gefitinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
cemiplimab
2
auricularum
2
atezolizumab
2
apatinib
2
Vemurafenib
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Ramucirumab
2
Calcium Dobesilate
2
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Non-Small-Cell Lung
×
Radiosurgery
×
Clear all
NCT02759783
2019-08-21
CORE
Royal Marsden NHS Foundation Trust
Phase 2/3
Unknown
245 enrolled